Faeth Therapeutics, Inc.

NASDAQ:FTH

Biotechnology

Healthcare
$8.72 +5.01%

+$1.43 today

Market cap
$224.79M
Beta
-0.31
P/E (TTM)
-0.2
EPS (TTM)
-$34.65
52W Low $7.21High $37.90

Volume 0.33M

Average 0.12M

FTH Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Faeth Therapeutics, Inc.NASDAQ: FTH

Retained Earnings · Q2 FY2026 · quarter ended Jun 2026

Retained earnings remains negative

Q2 FY2026 retained earnings was -$469.38M, compared with -$273.85M a year earlier.

Context

  • Retained earnings amounted to 247.9% of total assets at the end of Q2 FY2026, down 613.7 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -71.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$469.38M-3.5% QoQ
Last fiscal yearDec 2025
-$283.14M-8.0% YoY
Year agoJun 2025
-$273.85M-71.4% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.4%——
1 year-8.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(283.14M) USD
Year-over-year change
-8.0%

Retained Earnings vs competitors

How FTH compares with its peers on the latest reported figures

  • FTH's Jun 2026 retained earnings of -$469.38M is the 3rd highest of the 10 companies compared; the peer median is -$1.17B.
  • Its year-over-year change of -71.4% is the lowest of 10, against a peer median of -19.2%.
  • Retained earnings amounts to 247.9% of total assets for FTH, versus a peer median of 193.8%.
FTH Competitors Peer median
Retained Earnings for FTH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BOLDBoundless Bio, Inc.Mar 2026-$273.22M -25.8%—193.8%
JANXJanux Therapeutics, Inc.Mar 2026-$375.74M -43.8%—36.5%
FTHFaeth Therapeutics, Inc.Jun 2026-$469.38M -71.4%—247.9%
PRLDPrelude Therapeutics IncorporatedMar 2026-$693.45M -12.6%—579.6%
TNGXTango Therapeutics, Inc.Sep 2026-$772.4M -36.9%—74.7%
NUVBNuvation Bio Inc.Jun 2026-$1.17B -14.6%—157.5%
VSTMVerastem, Inc.Mar 2026-$1.2B -19.2%—527.5%
KURAKura Oncology, Inc.Mar 2026-$1.25B -30.9%—191.2%
PBYIPuma Biotechnology, Inc.Mar 2026-$1.29B +1.9%—668.2%
RLAYRelay Therapeutics, Inc.Jun 2026-$2.17B -15.2%—224.5%
Peer median (excluding FTH) -$1.17B-19.2%—193.8%

Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents7.16M17.8M13.01M9.99M8.67M
Short-term Investments140.46M89.32M52.75M31.34M12.52M
Net Receivables00000
Inventory00000
Other Current Assets374K344K325K120K92K
Total Current Assets148.54M108.59M67.25M41.93M21.51M
Property, Plant & Equipment (Net)4.64M9.72M7.04M3.38M1.38M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets39K63K86K48K18K
Total Non-current Assets4.68M9.79M7.12M3.43M1.4M
Total Assets153.23M118.38M74.37M45.36M22.9M
Account Payables2.46M4.47M1.69M244K689K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0002.01M1.4M
Total Current Liabilities4.89M9.07M5.64M5.45M4.25M
Long-term Debt000059K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities149K067K00
Total Non-current Liabilities1.82M5.9M3.84M1.53M59K
Total Liabilities6.71M14.97M9.48M6.98M4.31M
Common Stock3K3K3K3K0
Retained Earnings(149.21M)(197.79M)(231.9M)(262.05M)(283.14M)
Accumulated OCI(333K)(1M)(209K)(13K)1K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity146.51M103.41M64.9M38.39M18.59M
Total Debt2.35M8.03M6.21M3.85M1.51M
Net Debt(4.81M)(9.76M)(6.8M)(6.15M)(7.16M)

Faeth Therapeutics, Inc.

NASDAQ:FTH

Intrinsic Alpha fair value

Locked

Current Price

$8.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.